To the Editor We have read with great interest the article by Munson and colleagues1 in a recent issue of JAMA Internal Medicine exploring the use of prescription drugs associated with fracture risk in patients with fragility fractures. At the time of fracture, about three-quarters of patients were receiving at least 1 drug associated with increased fracture risk. The prescription pattern did not substantially change following the fracture event.
Matteo Cesari, Riccardo Calvani, Emanuele Marzetti. Where Is the Geriatrician?. JAMA Intern Med. 2017;177(3):441–442. doi:10.1001/jamainternmed.2016.8853